Heidelberg Bluepeak 光相干断层扫描仪
Ophthalmic drug development requires in-depth and comprehensive understandings about clinical ophthalmic diseases. As it is based on the specific expression changes of ophthalmic diseases and target tissues, it sets high standards for the R&D team's qualifications and experiences in relevant fields. Moreover, there is the basic requirement for professional, skillful clinical microsurgery during new ophthalmic drug development, which sets a very high threshold. InnoStar‘s integrated ophthalmic assessment platform focuses on pharmacodynamic, pharmacokinetic and nonclinical safety studies with drugs for ophthalmic diseases. The platform has an experienced and technologically-advanced research team that can ensure scientific and professional assessment and operation.
Focusing on efficacy, pharmacokinetic and toxicity assessment of drugs for ophthalmic diseases
● Experienced and technologically-advanced research team
● Advanced drug delivery technologies and means for examination and analysis
● A wide range of pharmacodynamic models for diseases
● Excellent equipment and instruments
Equipped with excellent ophthalmic instruments and equipment, InnoStar has established an integrated ophthalmology platform consisting of various ophthalmic disease models. Led by a medical expert with many years of clinical ophthalmic experience, InnoStar implements a wide range of ophthalmic specialty drug deliveries and carries out nonclinical studies, providing stable, high-quality, one-stop preclinical ophthalmic services for customers.
Address: 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, China
Postcode: 201203
Tel: +86-21-60211999
services@innostar.cn
86-021-xxxxxxx
Scan the QR code
Subscription to our Wechat account
Copyright © 2017-2021©中国·手机球探(bet007认证)官方网站-Macau App Station. All Rights Reserved. Created By VPABrand.com
